View ValuationFamiCord 향후 성장Future 기준 점검 4/6FamiCord (는) 각각 연간 104.4% 및 2.9% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 99.3% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 27.1% 로 예상됩니다.핵심 정보104.4%이익 성장률99.34%EPS 성장률Healthcare 이익 성장12.7%매출 성장률2.9%향후 자기자본이익률27.10%애널리스트 커버리지Low마지막 업데이트04 May 2026최근 향후 성장 업데이트공시 • Nov 22FamiCord AG Confirms Earnings Guidance for the Financial Year 2025FamiCord AG confirmed earnings guidance for the financial year 2025. On the basis of the performance in the first nine months of 2025, the Management Board looks to the remaining months of the year with confidence. The combination of solid revenue growth with attractive gross margins, a strong improvement in EBITDA, a positive operating cash flow despite the shift towards recurring revenues and a stable financial position provides a robust foundation. Against this backdrop, the Management Board confirms its outlook for the full year 2025, which continues to assume revenues of between EUR 85 million and EUR 95 million.Price Target Changed • Sep 03Price target increased by 19% to €7.50Up from €6.30, the current price target is provided by 1 analyst. New target price is 10% above last closing price of €6.80. Stock is up 45% over the past year. The company is forecast to post earnings per share of €0.04 next year compared to a net loss per share of €0.70 last year.Price Target Changed • May 06Price target increased by 8.3% to €6.50Up from €6.00, the current price target is provided by 1 analyst. New target price is 65% above last closing price of €3.94. Stock is down 17% over the past year. The company is forecast to post a net loss per share of €0.01 next year compared to a net loss per share of €0.70 last year.Major Estimate Revision • Dec 01Consensus estimates of losses per share improve by 38%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has improved. 2024 revenue forecast increased from €81.0m to €82.0m. EPS estimate increased from -€0.08 per share to -€0.05 per share. Healthcare industry in Germany expected to see average net income decline 4.2% next year. Consensus price target of €6.30 unchanged from last update. Share price was steady at €4.12 over the past week.Major Estimate Revision • Jun 09Consensus estimates of losses per share improve by 33%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has improved. 2024 revenue forecast increased from €79.1m to €81.0m. EPS estimate increased from -€0.12 per share to -€0.08 per share. Healthcare industry in Germany expected to see average net income growth of 16% next year. Consensus price target up from €5.30 to €6.00. Share price rose 3.0% to €4.86 over the past week.Price Target Changed • Jun 05Price target increased by 15% to €6.00Up from €5.21, the current price target is provided by 1 analyst. New target price is 22% above last closing price of €4.92. Stock is down 20% over the past year. The company is forecast to post a net loss per share of €0.08 next year compared to a net loss per share of €0.12 last year.모든 업데이트 보기Recent updates공시 • May 14FamiCord AG, Annual General Meeting, Jun 24, 2026FamiCord AG, Annual General Meeting, Jun 24, 2026, at 11:00 W. Europe Standard Time.Reported Earnings • May 05Full year 2025 earnings released: €0.26 loss per share (vs €0.70 loss in FY 2024)Full year 2025 results: €0.26 loss per share (improved from €0.70 loss in FY 2024). Revenue: €88.2m (up 7.3% from FY 2024). Net loss: €4.61m (loss narrowed 62% from FY 2024). Revenue is forecast to grow 2.9% p.a. on average during the next 3 years, compared to a 4.1% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.New Risk • May 03New major risk - Revenue and earnings growthEarnings have declined by 15% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 15% per year over the past 5 years. Minor Risk Market cap is less than US$100m (€77.4m market cap, or US$90.7m).New Risk • Mar 09New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €83.3m (US$96.8m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company.분석 기사 • Jan 28Is FamiCord (ETR:V3V) Using Debt In A Risky Way?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...공시 • Dec 24+ 3 more updatesFamiCord AG to Report Q3, 2026 Results on Nov 23, 2026FamiCord AG announced that they will report Q3, 2026 results on Nov 23, 2026분석 기사 • Dec 13FamiCord AG (ETR:V3V) Stock Rockets 28% As Investors Are Less Pessimistic Than ExpectedFamiCord AG ( ETR:V3V ) shares have had a really impressive month, gaining 28% after a shaky period beforehand. Looking...Reported Earnings • Nov 23Third quarter 2025 earnings released: EPS: €0.074 (vs €0.06 in 3Q 2024)Third quarter 2025 results: EPS: €0.074 (up from €0.06 in 3Q 2024). Revenue: €22.8m (up 2.5% from 3Q 2024). Net income: €1.24m (up 14% from 3Q 2024). Profit margin: 5.4% (up from 4.9% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.5% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.공시 • Nov 22FamiCord AG Confirms Earnings Guidance for the Financial Year 2025FamiCord AG confirmed earnings guidance for the financial year 2025. On the basis of the performance in the first nine months of 2025, the Management Board looks to the remaining months of the year with confidence. The combination of solid revenue growth with attractive gross margins, a strong improvement in EBITDA, a positive operating cash flow despite the shift towards recurring revenues and a stable financial position provides a robust foundation. Against this backdrop, the Management Board confirms its outlook for the full year 2025, which continues to assume revenues of between EUR 85 million and EUR 95 million.분석 기사 • Sep 23Is FamiCord (ETR:V3V) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Price Target Changed • Sep 03Price target increased by 19% to €7.50Up from €6.30, the current price target is provided by 1 analyst. New target price is 10% above last closing price of €6.80. Stock is up 45% over the past year. The company is forecast to post earnings per share of €0.04 next year compared to a net loss per share of €0.70 last year.분석 기사 • Aug 26Subdued Growth No Barrier To FamiCord AG (ETR:V3V) With Shares Advancing 33%Despite an already strong run, FamiCord AG ( ETR:V3V ) shares have been powering on, with a gain of 33% in the last...New Risk • Aug 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 9.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.분석 기사 • Jul 10FamiCord AG (ETR:V3V) Stocks Shoot Up 26% But Its P/S Still Looks ReasonableFamiCord AG ( ETR:V3V ) shares have continued their recent momentum with a 26% gain in the last month alone. Taking a...공시 • May 16FamiCord AG, Annual General Meeting, Jun 25, 2025FamiCord AG, Annual General Meeting, Jun 25, 2025, at 10:00 W. Europe Standard Time.Price Target Changed • May 06Price target increased by 8.3% to €6.50Up from €6.00, the current price target is provided by 1 analyst. New target price is 65% above last closing price of €3.94. Stock is down 17% over the past year. The company is forecast to post a net loss per share of €0.01 next year compared to a net loss per share of €0.70 last year.Reported Earnings • May 04Full year 2024 earnings: EPS misses analyst expectationsFull year 2024 results: €0.70 loss per share (further deteriorated from €0.12 loss in FY 2023). Revenue: €82.2m (up 6.6% from FY 2023). Net loss: €12.1m (loss widened €10.3m from FY 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates significantly. Revenue is forecast to grow 2.9% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.공시 • Jan 09+ 3 more updatesVITA 34 AG to Report Q1, 2025 Results on May 28, 2025VITA 34 AG announced that they will report Q1, 2025 results on May 28, 2025Major Estimate Revision • Dec 01Consensus estimates of losses per share improve by 38%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has improved. 2024 revenue forecast increased from €81.0m to €82.0m. EPS estimate increased from -€0.08 per share to -€0.05 per share. Healthcare industry in Germany expected to see average net income decline 4.2% next year. Consensus price target of €6.30 unchanged from last update. Share price was steady at €4.12 over the past week.New Risk • Nov 25New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 17% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 17% per year for the foreseeable future. Minor Risks Large one-off items impacting financial results. Shareholders have been diluted in the past year (10% increase in shares outstanding). Market cap is less than US$100m (€72.5m market cap, or US$75.5m).Reported Earnings • Sep 01Second quarter 2024 earnings released: €0.10 loss per share (vs €0.07 loss in 2Q 2023)Second quarter 2024 results: €0.10 loss per share (further deteriorated from €0.07 loss in 2Q 2023). Revenue: €19.5m (up 6.0% from 2Q 2023). Net loss: €1.41m (loss widened 19% from 2Q 2023). Revenue is forecast to grow 3.3% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 33% per year, which means it is performing significantly worse than earnings.Major Estimate Revision • Jun 09Consensus estimates of losses per share improve by 33%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has improved. 2024 revenue forecast increased from €79.1m to €81.0m. EPS estimate increased from -€0.12 per share to -€0.08 per share. Healthcare industry in Germany expected to see average net income growth of 16% next year. Consensus price target up from €5.30 to €6.00. Share price rose 3.0% to €4.86 over the past week.Reported Earnings • Jun 05First quarter 2024 earnings released: €0.05 loss per share (vs €0.18 loss in 1Q 2023)First quarter 2024 results: €0.05 loss per share (improved from €0.18 loss in 1Q 2023). Revenue: €18.6m (up 3.6% from 1Q 2023). Net loss: €785.0k (loss narrowed 73% from 1Q 2023). Revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has only fallen by 34% per year, which means it has not declined as severely as earnings.Price Target Changed • Jun 05Price target increased by 15% to €6.00Up from €5.21, the current price target is provided by 1 analyst. New target price is 22% above last closing price of €4.92. Stock is down 20% over the past year. The company is forecast to post a net loss per share of €0.08 next year compared to a net loss per share of €0.12 last year.Breakeven Date Change • May 02No longer forecast to breakevenThe analyst covering VITA 34 no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of €1.05m in 2024. New forecast suggests the company will make a loss of €1.50m in 2025.공시 • Apr 27+ 3 more updatesVITA 34 AG to Report Q1, 2024 Results on May 31, 2024VITA 34 AG announced that they will report Q1, 2024 results on May 31, 2024New Risk • Apr 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€1.7m net loss in 2 years). Share price has been volatile over the past 3 months (6.8% average weekly change). Shareholders have been diluted in the past year (10% increase in shares outstanding). Market cap is less than US$100m (€78.8m market cap, or US$83.8m).New Risk • Apr 04New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: €25m Forecast net loss in 2 years: €1.7m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€1.7m net loss in 2 years). Shareholders have been diluted in the past year (10% increase in shares outstanding).분석 기사 • Apr 04Why We're Not Concerned About VITA 34 AG's (ETR:V3V) Share PriceWhen close to half the companies in the Healthcare industry in Germany have price-to-sales ratios (or "P/S") below...New Risk • Feb 12New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 10% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (10% increase in shares outstanding). Market cap is less than US$100m (€86.3m market cap, or US$93.1m).분석 기사 • Dec 24Revenues Tell The Story For VITA 34 AG (ETR:V3V) As Its Stock Soars 26%VITA 34 AG ( ETR:V3V ) shareholders would be excited to see that the share price has had a great month, posting a 26...Reported Earnings • Nov 26Third quarter 2023 earnings released: €0.10 loss per share (vs €0.02 loss in 3Q 2022)Third quarter 2023 results: €0.10 loss per share (further deteriorated from €0.02 loss in 3Q 2022). Revenue: €20.4m (up 9.4% from 3Q 2022). Net loss: €1.62m (loss widened €1.41m from 3Q 2022). Revenue is forecast to grow 6.4% p.a. on average during the next 3 years, compared to a 1.6% decline forecast for the Healthcare industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 64 percentage points per year, which is a significant difference in performance.분석 기사 • Nov 23Is VITA 34 (ETR:V3V) Using Too Much Debt?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Reported Earnings • Sep 01Second quarter 2023 earnings released: €0.07 loss per share (vs €0.30 loss in 2Q 2022)Second quarter 2023 results: €0.07 loss per share (improved from €0.30 loss in 2Q 2022). Revenue: €18.4m (up 10% from 2Q 2022). Net loss: €1.19m (loss narrowed 74% from 2Q 2022). Revenue is forecast to grow 7.2% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 76 percentage points per year, which is a significant difference in performance.분석 기사 • Jul 15Is VITA 34 (ETR:V3V) Using Debt In A Risky Way?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Major Estimate Revision • Jul 05Consensus EPS estimates fall by 28%, revenue upgradedThe consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast increased from €75.0m to €76.0m. Forecast EPS reduced from -€0.09 to -€0.115 per share. Healthcare industry in Germany expected to see average net income growth of 15% next year. Consensus price target down from €9.25 to €6.81. Share price rose 2.2% to €5.64 over the past week.New Risk • Jun 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.1% average weekly change). Market cap is less than US$100m (€83.6m market cap, or US$91.2m).New Risk • Jun 13New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €83.6m (US$90.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company.Reported Earnings • Jun 02First quarter 2023 earnings released: €0.18 loss per share (vs €0.18 loss in 1Q 2022)First quarter 2023 results: €0.18 loss per share (in line with 1Q 2022). Revenue: €17.9m (up 16% from 1Q 2022). Net loss: €2.89m (loss widened 2.8% from 1Q 2022). Revenue is forecast to grow 9.7% p.a. on average during the next 3 years, compared to a 4.6% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 92 percentage points per year, which is a significant difference in performance.공시 • May 12Vita 34 Ag Starts Recruitment for Clinical Trial with Car-T Drug CandidateVita 34 AG has started enrollment in Phase I of the Tarcidomgen Kimleucel clinical trial. The drug candidate is an anti-CD19 CAR-T, a chimeric antigen receptor, and the first candidate in Vita 34's Cell & Gene Therapy (CGT) portfolio. After recent clearance by the responsible authorities and the responsible ethics committee, the start of the clinical trial under the name CARLA and the recruitment of the first patient ("First Patient In") is imminent. A total of up to ten patients are expected to be recruited for Phase I of the study, which is the usual number for this type of drug. The recruitment will take place via two clinical centers in Poland. The Management Board of Vita 34 AG expects Phase I to be completed by the end of 2023. The costs related with this phase of the trial have already taken into consideration in the guidance published for 2023. The principal investigator of the CARLA study is Prof. Grzegorz Basak, Professor and Chairman of the Department of Hematology, Transplantation and Internal Medicine at the University Hospital of Warsaw Medical University. Tarcidomgen Kimlucel is being developed through FamiCordTx, a subsidiary of Vita 34 AG that aims to develop proprietary CAR-T drug therapies. FamiCordTx has secured an exclusive license from a U.S. supplier for this purpose in the past and has optimized the technology according to European GMP standards. CAR-T therapy uses a patient's own T cells, which are genetically engineered in a laboratory to produce a protein called a chimeric antigen receptor (CAR). When the modified T-cells are returned to the patient, the CAR enables the T- cells to seek out and destroy cancer cells wherever they are in the body. According to a report by Allied Market Research, the global CAR-T cell therapy market was valued USD 1,7 billion in 2021 and is expected to reach USD 6.1 billion by 2031.Reported Earnings • May 02Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2022 results: €1.71 loss per share (further deteriorated from €0.63 loss in FY 2021). Revenue: €68.9m (up 143% from FY 2021). Net loss: €27.1m (loss widened €23.4m from FY 2021). Revenue exceeded analyst estimates by 1.8%. Earnings per share (EPS) missed analyst estimates significantly. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 100 percentage points per year, which is a significant difference in performance.분석 기사 • Feb 17Is VITA 34 (ETR:V3V) Using Debt In A Risky Way?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...공시 • Dec 03+ 4 more updatesVITA 34 AG to Report Q3, 2023 Results on Nov 21, 2023VITA 34 AG announced that they will report Q3, 2023 results on Nov 21, 2023Major Estimate Revision • Dec 01Consensus estimates of losses per share improve by 10%The consensus outlook for earnings per share (EPS) in 2022 has improved. 2022 revenue forecast increased from €66.5m to €67.7m. EPS estimate increased from -€0.59 per share to -€0.53 per share. Healthcare industry in Germany expected to see average net income decline 6.2% next year. Consensus price target of €10.50 unchanged from last update. Share price fell 7.6% to €8.32 over the past week.Reported Earnings • Nov 24Third quarter 2022 earnings released: €0.02 loss per share (vs €0.11 profit in 3Q 2021)Third quarter 2022 results: €0.02 loss per share (down from €0.11 profit in 3Q 2021). Revenue: €18.7m (up 230% from 3Q 2021). Net loss: €209.0k (down 147% from profit in 3Q 2021). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 98 percentage points per year, which is a significant difference in performance.Price Target Changed • Nov 16Price target decreased to €10.50Down from €12.50, the current price target is an average from 2 analysts. New target price is 17% above last closing price of €9.00. Stock is down 46% over the past year. The company is forecast to post a net loss per share of €0.59 next year compared to a net loss per share of €0.63 last year.Reported Earnings • Sep 01Second quarter 2022 earnings released: EPS: €0.30 (vs €0.002 loss in 2Q 2021)Second quarter 2022 results: EPS: €0.30. Revenue: €16.6m (up 206% from 2Q 2021). Net loss: €4.61m (loss widened €4.60m from 2Q 2021). Over the next year, revenue is forecast to grow 48%, compared to a 3.7% growth forecast for the Healthcare industry in Germany.공시 • Aug 31VITA 34 AG Revises Earnings Guidance for the Financial Year 2022VITA 34 AG revised earnings guidance for the financial year 2022. For the year, the company adjusting the forecast ranges for consolidated sales to EUR 65 to EUR 72 million (previously: EUR 68 to EUR 75 million).공시 • Aug 24VITA 34 AG to Report Q2, 2022 Results on Aug 30, 2022VITA 34 AG announced that they will report Q2, 2022 results on Aug 30, 2022공시 • Jun 30+ 1 more updateVITA 34 AG, Annual General Meeting, Jun 29, 2022VITA 34 AG, Annual General Meeting, Jun 29, 2022. Agenda: To consider new Chief Financial Officer; and to consider other matters.Major Estimate Revision • Jun 07Consensus EPS estimates fall by 85%The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from €73.4m to €68.9m. Losses expected to increase from €0.27 per share to €0.50. Healthcare industry in Germany expected to see average net income growth of 6.5% next year. Consensus price target down from €14.00 to €13.00. Share price rose 2.3% to €11.35 over the past week.Reported Earnings • Jun 02First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behindFirst quarter 2022 results: €0.18 loss per share (down from €0.01 loss in 1Q 2021). Revenue: €15.5m (up 188% from 1Q 2021). Net loss: €2.81m (loss widened €2.77m from 1Q 2021). Revenue exceeded analyst estimates by 29%. Earnings per share (EPS) missed analyst estimates. Over the next year, revenue is forecast to grow 103%, compared to a 4.8% growth forecast for the industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 72 percentage points per year, which is a significant difference in performance.공시 • May 25VITA 34 AG to Report Q1, 2022 Results on May 31, 2022VITA 34 AG announced that they will report Q1, 2022 results on May 31, 2022Reported Earnings • May 02Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2021 results: €0.63 loss per share (down from €0.37 profit in FY 2020). Revenue: €28.4m (up 42% from FY 2020). Net loss: €3.67m (down 343% from profit in FY 2020). Revenue exceeded analyst estimates by 29%. Earnings per share (EPS) missed analyst estimates. Over the next year, revenue is expected to shrink by 17% compared to a 5.9% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.공시 • May 02Vita 34 Ag Provides Revenue Guidance for the Financial Year 2022VITA 34 AG provided revenue guidance for the financial year 2022. For the year, the company expects consolidated revenues of between EUR 68 million and EUR 75 million for the full year 2022 (2021: EUR 28.4 million).Price Target Changed • Apr 27Price target increased to €25.00Up from €19.10, the current price target is provided by 1 analyst. New target price is 109% above last closing price of €11.95. Stock is down 29% over the past year. The company is forecast to post earnings per share of €0.46 for next year compared to €0.37 last year.분석 기사 • Apr 08Is It Too Late To Consider Buying VITA 34 AG (ETR:V3V)?VITA 34 AG ( ETR:V3V ), might not be a large cap stock, but it saw a double-digit share price rise of over 10% in the...Price Target Changed • Dec 18Price target increased to €21.10Up from €19.10, the current price target is an average from 2 analysts. New target price is 35% above last closing price of €15.60. Stock is up 27% over the past year. The company is forecast to post earnings per share of €0.46 for next year compared to €0.37 last year.분석 기사 • Dec 07VITA 34 AG's (ETR:V3V) CEO Compensation Looks Acceptable To Us And Here's WhyDespite strong share price growth of 39% for VITA 34 AG ( ETR:V3V ) over the last few years, earnings growth has been...Reported Earnings • Nov 12Third quarter 2021 earnings released: EPS €0.14 (vs €0.18 in 3Q 2020)The company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: €5.82m (up 7.4% from 3Q 2020). Net income: €575.0k (down 23% from 3Q 2020). Profit margin: 9.9% (down from 14% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.Reported Earnings • Sep 01Second quarter 2021 earnings releasedThe company reported a soft second quarter result with weaker earnings and weaker control over costs, although revenues improved. Second quarter 2021 results: Revenue: €5.44m (up 11% from 2Q 2020). Net loss: €12.0k (down 102% from profit in 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 2% per year whereas the company’s share price has increased by 3% per year.Major Estimate Revision • Jun 08Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast fell from €22.0m to €21.8m. EPS estimate rose from €0.47 to €0.52. Net income forecast to grow 92% next year vs 92% growth forecast for Healthcare industry in Germany. Consensus price target of €19.10 unchanged from last update. Share price was steady at €17.05 over the past week.공시 • Jun 02VITA 34 AG (XTRA:V3V) entered into a Business Combination Agreement to acquire Polski Bank Komórek Macierzystych S.A. (WSE:BKM) (PKBM) from AOC Health GmbH, Jakub Baran, Tomasz Baran and others for approximately PLN 840 million.VITA 34 AG (XTRA:V3V) entered into a Business Combination Agreement to acquire Polski Bank Komórek Macierzystych S.A. (WSE:BKM) (PKBM) from AOC Health GmbH, Jakub Baran, Tomasz Baran and others for approximately PLN 840 million on May 31, 2021. Transaction to be carried out by way of a contribution in kind at an exchange of 1.3 new Vita 34 shares in exchange for one (1) share of PBKM. Under the transaction, AOC Health GmbH will sell 5.743221 million shares representing 62.4% stake, Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A. will sell 1.282201 million shares representing 13.93% stake and Jakub Baran will sell 0.395875 million shares representing 4.3% stake. Major PBKM shareholders have already agreed to contribute to Vita 34 a total of 6.363170 million PBKM shares (representing approximately 69.13% of the current share capital of PBKM). The combined Group will be listed on the Frankfurt Stock Exchange, with Vita 34 as the listed parent company. These shareholders include (inter alia) AOC Health GmbH, Jakub Baran, President and Chief Executive officer of the PBKM Management Board, and Tomasz Baran, Vice President and Deputy Chief Executive officer of the PBKM Management Board. The new Vita 34 shares to be issued under the Proposed Transaction shall be created by way of a capital increase in kind still to be resolved upon by Vita 34’s shareholders. For purposes of resolving the capital increase, Vita 34 will convene an extraordinary general meeting for July 13, 2021, with the ordinary annual general meeting originally scheduled for June 30, 2021 to be postponed and likely to take place in the fourth quarter of 2021. At the extraordinary general meeting, Vita 34’s share capital shall be increased by up to €12.280560 million against contribution in kind by issuing up to 12,280,560 no-par value registered shares. Completion of the Exchange Offer is subject to a number of conditions, including the achievement of a minimum acceptance level of 95% of PBKM’s outstanding shares and the absence of any material adverse change and no material adverse infringements occurring at PBKM. Transaction has been approved by the Supervisory Board of Vita 34 AG. The Management Board PBKM intends to support the Proposed Transaction and recommend to the PBKM shareholders to accept the Exchange Offer. Transaction is expected to complete by the end of October 2021. VITA 34 AG appointed ValueTrust Financial Advisors SE as an independent expert under the transaction.Reported Earnings • Jun 01First quarter 2021 earnings releasedThe company reported a soft first quarter result with weaker earnings and weaker control over costs, although revenues improved. First quarter 2021 results: Revenue: €5.38m (up 15% from 1Q 2020). Net loss: €38.0k (down 110% from profit in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.공시 • Jun 01VITA 34 AG Provides Earnings Guidance for the Year 2021VITA 34 AG maintained guidance for 2021. The Management Board maintains its guidance for the full fiscal year 2021 of Vita 34 AG (prior to the planned merger) published in the context of the Annual Report 2020.분석 기사 • May 12Is It Too Late To Consider Buying VITA 34 AG (ETR:V3V)?While VITA 34 AG ( ETR:V3V ) might not be the most widely known stock at the moment, it saw a significant share price...Major Estimate Revision • Apr 07Consensus EPS estimates fall to €0.47The consensus outlook for earnings per share (EPS) in 2021 has deteriorated. 2021 revenue forecast decreased from €22.3m to €22.0m. EPS estimate also fell from €0.61 to €0.47. Net income forecast to grow 26% next year vs 16% growth forecast for Healthcare industry in Germany. Consensus price target up from €20.00 to €21.00. Share price rose 2.3% to €15.25 over the past week.분석 기사 • Apr 03Earnings Miss: VITA 34 AG Missed EPS By 29% And Analysts Are Revising Their ForecastsVITA 34 AG ( ETR:V3V ) missed earnings with its latest full-year results, disappointing overly-optimistic forecasters...Reported Earnings • Apr 01Full year 2020 earnings released: EPS €0.37 (vs €0.18 in FY 2019)The company reported a solid full year result with improved earnings and profit margins, although revenues were flat. Full year 2020 results: Revenue: €20.1m (flat on FY 2019). Net income: €1.51m (up 104% from FY 2019). Profit margin: 7.5% (up from 3.7% in FY 2019). Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.분석 기사 • Mar 25VITA 34 AG's (ETR:V3V) Intrinsic Value Is Potentially 56% Above Its Share PriceHow far off is VITA 34 AG ( ETR:V3V ) from its intrinsic value? Using the most recent financial data, we'll take a look...공시 • Mar 17+ 3 more updatesVITA 34 AG to Report Q1, 2021 Results on May 11, 2021VITA 34 AG announced that they will report Q1, 2021 results on May 11, 2021분석 기사 • Mar 10Should You Be Adding VITA 34 (ETR:V3V) To Your Watchlist Today?Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...분석 기사 • Feb 22Here's Why VITA 34 (ETR:V3V) Can Manage Its Debt ResponsiblyDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Is New 90 Day High Low • Feb 10New 90-day high: €13.95The company is up 11% from its price of €12.60 on 11 November 2020. The German market is also up 11% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it outperformed the Healthcare industry, which is down 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €22.83 per share.분석 기사 • Feb 05Is It Too Late To Consider Buying VITA 34 AG (ETR:V3V)?VITA 34 AG ( ETR:V3V ), might not be a large cap stock, but it led the XTRA gainers with a relatively large price hike...Is New 90 Day High Low • Jan 23New 90-day high: €13.05The company is up 4.0% from its price of €12.55 on 23 October 2020. The German market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €22.88 per share.분석 기사 • Jan 18Can Mixed Financials Have A Negative Impact on VITA 34 AG's 's (ETR:V3V) Current Price Momentum?Most readers would already know that VITA 34's (ETR:V3V) stock increased by 4.5% over the past month. However, we...분석 기사 • Jan 02Did You Participate In Any Of VITA 34's (ETR:V3V) Fantastic 201% Return ?The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...공시 • Dec 19VITA 34 AG, Annual General Meeting, Jun 30, 2021VITA 34 AG, Annual General Meeting, Jun 30, 2021.분석 기사 • Dec 18How Is VITA 34's (ETR:V3V) CEO Compensated?This article will reflect on the compensation paid to Wolfgang Knirsch who has served as CEO of VITA 34 AG ( ETR:V3V...분석 기사 • Dec 01Should You Be Adding VITA 34 (ETR:V3V) To Your Watchlist Today?Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...Price Target Changed • Nov 26Price target raised to €17.50Up from €15.00, the current price target is an average from 2 analysts. The new target price is 39% above the current share price of €12.55. As of last close, the stock is down 4.9% over the past year.이익 및 매출 성장 예측XTRA:V3V - 애널리스트 향후 추정치 및 과거 재무 데이터 (EUR Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/202892246112/31/202788125112/31/202685047112/31/202588-5-14N/A9/30/202588-1004N/A6/30/202588-1015N/A3/31/202586-1246N/A12/31/202482-1159N/A9/30/2024814912N/A6/30/2024791711N/A3/31/2024780711N/A12/31/202377-259N/A9/30/202375-25-50N/A6/30/202373-24-61N/A3/31/202371-27-10-3N/A12/31/202269-27-11-4N/A9/30/202263-12-60N/A6/30/202250-11-5-1N/A3/31/202239-6-12N/A12/31/202128-403N/A9/30/202121023N/A6/30/202121033N/A3/31/202120134N/A12/31/202020134N/A9/30/202020145N/A6/30/202020156N/A3/31/202020156N/A12/31/201920156N/A9/30/2019201N/A6N/A6/30/2019201N/A5N/A3/31/2019201N/A5N/A12/31/2018201N/A5N/A9/30/2018212N/A4N/A6/30/2018211N/A3N/A3/31/2018200N/A2N/A12/31/2017190N/A2N/A9/30/201718-1N/A2N/A6/30/201716-1N/A2N/A3/31/2017171N/A2N/A12/31/2016160N/A2N/A9/30/2016162N/A1N/A6/30/2016162N/A1N/A3/31/2016152N/A1N/A12/31/2015142N/A3N/A9/30/2015141N/A2N/A6/30/2015141N/A2N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: V3V 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률(1.9%)보다 빠른 성장으로 간주됩니다.수익 vs 시장: V3V (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.고성장 수익: V3V 향후 3년 내에 수익을 낼 것으로 예상됩니다.수익 대 시장: V3V 의 수익(연간 2.9%)이 German 시장(연간 6.7%)보다 느리게 성장할 것으로 예상됩니다.고성장 매출: V3V 의 수익(연간 2.9%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: V3V의 자본 수익률은 3년 후 27.1%로 높을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YHealthcare 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/28 16:05종가2026/05/28 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스FamiCord AG는 3명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Emily HainesFirst Berlin Equity Research GmbHTim KruseMontega AGUlrich HuwaldWarburg Research GmbH
공시 • Nov 22FamiCord AG Confirms Earnings Guidance for the Financial Year 2025FamiCord AG confirmed earnings guidance for the financial year 2025. On the basis of the performance in the first nine months of 2025, the Management Board looks to the remaining months of the year with confidence. The combination of solid revenue growth with attractive gross margins, a strong improvement in EBITDA, a positive operating cash flow despite the shift towards recurring revenues and a stable financial position provides a robust foundation. Against this backdrop, the Management Board confirms its outlook for the full year 2025, which continues to assume revenues of between EUR 85 million and EUR 95 million.
Price Target Changed • Sep 03Price target increased by 19% to €7.50Up from €6.30, the current price target is provided by 1 analyst. New target price is 10% above last closing price of €6.80. Stock is up 45% over the past year. The company is forecast to post earnings per share of €0.04 next year compared to a net loss per share of €0.70 last year.
Price Target Changed • May 06Price target increased by 8.3% to €6.50Up from €6.00, the current price target is provided by 1 analyst. New target price is 65% above last closing price of €3.94. Stock is down 17% over the past year. The company is forecast to post a net loss per share of €0.01 next year compared to a net loss per share of €0.70 last year.
Major Estimate Revision • Dec 01Consensus estimates of losses per share improve by 38%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has improved. 2024 revenue forecast increased from €81.0m to €82.0m. EPS estimate increased from -€0.08 per share to -€0.05 per share. Healthcare industry in Germany expected to see average net income decline 4.2% next year. Consensus price target of €6.30 unchanged from last update. Share price was steady at €4.12 over the past week.
Major Estimate Revision • Jun 09Consensus estimates of losses per share improve by 33%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has improved. 2024 revenue forecast increased from €79.1m to €81.0m. EPS estimate increased from -€0.12 per share to -€0.08 per share. Healthcare industry in Germany expected to see average net income growth of 16% next year. Consensus price target up from €5.30 to €6.00. Share price rose 3.0% to €4.86 over the past week.
Price Target Changed • Jun 05Price target increased by 15% to €6.00Up from €5.21, the current price target is provided by 1 analyst. New target price is 22% above last closing price of €4.92. Stock is down 20% over the past year. The company is forecast to post a net loss per share of €0.08 next year compared to a net loss per share of €0.12 last year.
공시 • May 14FamiCord AG, Annual General Meeting, Jun 24, 2026FamiCord AG, Annual General Meeting, Jun 24, 2026, at 11:00 W. Europe Standard Time.
Reported Earnings • May 05Full year 2025 earnings released: €0.26 loss per share (vs €0.70 loss in FY 2024)Full year 2025 results: €0.26 loss per share (improved from €0.70 loss in FY 2024). Revenue: €88.2m (up 7.3% from FY 2024). Net loss: €4.61m (loss narrowed 62% from FY 2024). Revenue is forecast to grow 2.9% p.a. on average during the next 3 years, compared to a 4.1% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.
New Risk • May 03New major risk - Revenue and earnings growthEarnings have declined by 15% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 15% per year over the past 5 years. Minor Risk Market cap is less than US$100m (€77.4m market cap, or US$90.7m).
New Risk • Mar 09New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €83.3m (US$96.8m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company.
분석 기사 • Jan 28Is FamiCord (ETR:V3V) Using Debt In A Risky Way?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
공시 • Dec 24+ 3 more updatesFamiCord AG to Report Q3, 2026 Results on Nov 23, 2026FamiCord AG announced that they will report Q3, 2026 results on Nov 23, 2026
분석 기사 • Dec 13FamiCord AG (ETR:V3V) Stock Rockets 28% As Investors Are Less Pessimistic Than ExpectedFamiCord AG ( ETR:V3V ) shares have had a really impressive month, gaining 28% after a shaky period beforehand. Looking...
Reported Earnings • Nov 23Third quarter 2025 earnings released: EPS: €0.074 (vs €0.06 in 3Q 2024)Third quarter 2025 results: EPS: €0.074 (up from €0.06 in 3Q 2024). Revenue: €22.8m (up 2.5% from 3Q 2024). Net income: €1.24m (up 14% from 3Q 2024). Profit margin: 5.4% (up from 4.9% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.5% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.
공시 • Nov 22FamiCord AG Confirms Earnings Guidance for the Financial Year 2025FamiCord AG confirmed earnings guidance for the financial year 2025. On the basis of the performance in the first nine months of 2025, the Management Board looks to the remaining months of the year with confidence. The combination of solid revenue growth with attractive gross margins, a strong improvement in EBITDA, a positive operating cash flow despite the shift towards recurring revenues and a stable financial position provides a robust foundation. Against this backdrop, the Management Board confirms its outlook for the full year 2025, which continues to assume revenues of between EUR 85 million and EUR 95 million.
분석 기사 • Sep 23Is FamiCord (ETR:V3V) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
Price Target Changed • Sep 03Price target increased by 19% to €7.50Up from €6.30, the current price target is provided by 1 analyst. New target price is 10% above last closing price of €6.80. Stock is up 45% over the past year. The company is forecast to post earnings per share of €0.04 next year compared to a net loss per share of €0.70 last year.
분석 기사 • Aug 26Subdued Growth No Barrier To FamiCord AG (ETR:V3V) With Shares Advancing 33%Despite an already strong run, FamiCord AG ( ETR:V3V ) shares have been powering on, with a gain of 33% in the last...
New Risk • Aug 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 9.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
분석 기사 • Jul 10FamiCord AG (ETR:V3V) Stocks Shoot Up 26% But Its P/S Still Looks ReasonableFamiCord AG ( ETR:V3V ) shares have continued their recent momentum with a 26% gain in the last month alone. Taking a...
공시 • May 16FamiCord AG, Annual General Meeting, Jun 25, 2025FamiCord AG, Annual General Meeting, Jun 25, 2025, at 10:00 W. Europe Standard Time.
Price Target Changed • May 06Price target increased by 8.3% to €6.50Up from €6.00, the current price target is provided by 1 analyst. New target price is 65% above last closing price of €3.94. Stock is down 17% over the past year. The company is forecast to post a net loss per share of €0.01 next year compared to a net loss per share of €0.70 last year.
Reported Earnings • May 04Full year 2024 earnings: EPS misses analyst expectationsFull year 2024 results: €0.70 loss per share (further deteriorated from €0.12 loss in FY 2023). Revenue: €82.2m (up 6.6% from FY 2023). Net loss: €12.1m (loss widened €10.3m from FY 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates significantly. Revenue is forecast to grow 2.9% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.
공시 • Jan 09+ 3 more updatesVITA 34 AG to Report Q1, 2025 Results on May 28, 2025VITA 34 AG announced that they will report Q1, 2025 results on May 28, 2025
Major Estimate Revision • Dec 01Consensus estimates of losses per share improve by 38%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has improved. 2024 revenue forecast increased from €81.0m to €82.0m. EPS estimate increased from -€0.08 per share to -€0.05 per share. Healthcare industry in Germany expected to see average net income decline 4.2% next year. Consensus price target of €6.30 unchanged from last update. Share price was steady at €4.12 over the past week.
New Risk • Nov 25New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 17% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 17% per year for the foreseeable future. Minor Risks Large one-off items impacting financial results. Shareholders have been diluted in the past year (10% increase in shares outstanding). Market cap is less than US$100m (€72.5m market cap, or US$75.5m).
Reported Earnings • Sep 01Second quarter 2024 earnings released: €0.10 loss per share (vs €0.07 loss in 2Q 2023)Second quarter 2024 results: €0.10 loss per share (further deteriorated from €0.07 loss in 2Q 2023). Revenue: €19.5m (up 6.0% from 2Q 2023). Net loss: €1.41m (loss widened 19% from 2Q 2023). Revenue is forecast to grow 3.3% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 33% per year, which means it is performing significantly worse than earnings.
Major Estimate Revision • Jun 09Consensus estimates of losses per share improve by 33%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has improved. 2024 revenue forecast increased from €79.1m to €81.0m. EPS estimate increased from -€0.12 per share to -€0.08 per share. Healthcare industry in Germany expected to see average net income growth of 16% next year. Consensus price target up from €5.30 to €6.00. Share price rose 3.0% to €4.86 over the past week.
Reported Earnings • Jun 05First quarter 2024 earnings released: €0.05 loss per share (vs €0.18 loss in 1Q 2023)First quarter 2024 results: €0.05 loss per share (improved from €0.18 loss in 1Q 2023). Revenue: €18.6m (up 3.6% from 1Q 2023). Net loss: €785.0k (loss narrowed 73% from 1Q 2023). Revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has only fallen by 34% per year, which means it has not declined as severely as earnings.
Price Target Changed • Jun 05Price target increased by 15% to €6.00Up from €5.21, the current price target is provided by 1 analyst. New target price is 22% above last closing price of €4.92. Stock is down 20% over the past year. The company is forecast to post a net loss per share of €0.08 next year compared to a net loss per share of €0.12 last year.
Breakeven Date Change • May 02No longer forecast to breakevenThe analyst covering VITA 34 no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of €1.05m in 2024. New forecast suggests the company will make a loss of €1.50m in 2025.
공시 • Apr 27+ 3 more updatesVITA 34 AG to Report Q1, 2024 Results on May 31, 2024VITA 34 AG announced that they will report Q1, 2024 results on May 31, 2024
New Risk • Apr 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€1.7m net loss in 2 years). Share price has been volatile over the past 3 months (6.8% average weekly change). Shareholders have been diluted in the past year (10% increase in shares outstanding). Market cap is less than US$100m (€78.8m market cap, or US$83.8m).
New Risk • Apr 04New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: €25m Forecast net loss in 2 years: €1.7m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€1.7m net loss in 2 years). Shareholders have been diluted in the past year (10% increase in shares outstanding).
분석 기사 • Apr 04Why We're Not Concerned About VITA 34 AG's (ETR:V3V) Share PriceWhen close to half the companies in the Healthcare industry in Germany have price-to-sales ratios (or "P/S") below...
New Risk • Feb 12New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 10% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (10% increase in shares outstanding). Market cap is less than US$100m (€86.3m market cap, or US$93.1m).
분석 기사 • Dec 24Revenues Tell The Story For VITA 34 AG (ETR:V3V) As Its Stock Soars 26%VITA 34 AG ( ETR:V3V ) shareholders would be excited to see that the share price has had a great month, posting a 26...
Reported Earnings • Nov 26Third quarter 2023 earnings released: €0.10 loss per share (vs €0.02 loss in 3Q 2022)Third quarter 2023 results: €0.10 loss per share (further deteriorated from €0.02 loss in 3Q 2022). Revenue: €20.4m (up 9.4% from 3Q 2022). Net loss: €1.62m (loss widened €1.41m from 3Q 2022). Revenue is forecast to grow 6.4% p.a. on average during the next 3 years, compared to a 1.6% decline forecast for the Healthcare industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 64 percentage points per year, which is a significant difference in performance.
분석 기사 • Nov 23Is VITA 34 (ETR:V3V) Using Too Much Debt?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Reported Earnings • Sep 01Second quarter 2023 earnings released: €0.07 loss per share (vs €0.30 loss in 2Q 2022)Second quarter 2023 results: €0.07 loss per share (improved from €0.30 loss in 2Q 2022). Revenue: €18.4m (up 10% from 2Q 2022). Net loss: €1.19m (loss narrowed 74% from 2Q 2022). Revenue is forecast to grow 7.2% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 76 percentage points per year, which is a significant difference in performance.
분석 기사 • Jul 15Is VITA 34 (ETR:V3V) Using Debt In A Risky Way?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Major Estimate Revision • Jul 05Consensus EPS estimates fall by 28%, revenue upgradedThe consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast increased from €75.0m to €76.0m. Forecast EPS reduced from -€0.09 to -€0.115 per share. Healthcare industry in Germany expected to see average net income growth of 15% next year. Consensus price target down from €9.25 to €6.81. Share price rose 2.2% to €5.64 over the past week.
New Risk • Jun 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.1% average weekly change). Market cap is less than US$100m (€83.6m market cap, or US$91.2m).
New Risk • Jun 13New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €83.6m (US$90.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company.
Reported Earnings • Jun 02First quarter 2023 earnings released: €0.18 loss per share (vs €0.18 loss in 1Q 2022)First quarter 2023 results: €0.18 loss per share (in line with 1Q 2022). Revenue: €17.9m (up 16% from 1Q 2022). Net loss: €2.89m (loss widened 2.8% from 1Q 2022). Revenue is forecast to grow 9.7% p.a. on average during the next 3 years, compared to a 4.6% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 92 percentage points per year, which is a significant difference in performance.
공시 • May 12Vita 34 Ag Starts Recruitment for Clinical Trial with Car-T Drug CandidateVita 34 AG has started enrollment in Phase I of the Tarcidomgen Kimleucel clinical trial. The drug candidate is an anti-CD19 CAR-T, a chimeric antigen receptor, and the first candidate in Vita 34's Cell & Gene Therapy (CGT) portfolio. After recent clearance by the responsible authorities and the responsible ethics committee, the start of the clinical trial under the name CARLA and the recruitment of the first patient ("First Patient In") is imminent. A total of up to ten patients are expected to be recruited for Phase I of the study, which is the usual number for this type of drug. The recruitment will take place via two clinical centers in Poland. The Management Board of Vita 34 AG expects Phase I to be completed by the end of 2023. The costs related with this phase of the trial have already taken into consideration in the guidance published for 2023. The principal investigator of the CARLA study is Prof. Grzegorz Basak, Professor and Chairman of the Department of Hematology, Transplantation and Internal Medicine at the University Hospital of Warsaw Medical University. Tarcidomgen Kimlucel is being developed through FamiCordTx, a subsidiary of Vita 34 AG that aims to develop proprietary CAR-T drug therapies. FamiCordTx has secured an exclusive license from a U.S. supplier for this purpose in the past and has optimized the technology according to European GMP standards. CAR-T therapy uses a patient's own T cells, which are genetically engineered in a laboratory to produce a protein called a chimeric antigen receptor (CAR). When the modified T-cells are returned to the patient, the CAR enables the T- cells to seek out and destroy cancer cells wherever they are in the body. According to a report by Allied Market Research, the global CAR-T cell therapy market was valued USD 1,7 billion in 2021 and is expected to reach USD 6.1 billion by 2031.
Reported Earnings • May 02Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2022 results: €1.71 loss per share (further deteriorated from €0.63 loss in FY 2021). Revenue: €68.9m (up 143% from FY 2021). Net loss: €27.1m (loss widened €23.4m from FY 2021). Revenue exceeded analyst estimates by 1.8%. Earnings per share (EPS) missed analyst estimates significantly. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 100 percentage points per year, which is a significant difference in performance.
분석 기사 • Feb 17Is VITA 34 (ETR:V3V) Using Debt In A Risky Way?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
공시 • Dec 03+ 4 more updatesVITA 34 AG to Report Q3, 2023 Results on Nov 21, 2023VITA 34 AG announced that they will report Q3, 2023 results on Nov 21, 2023
Major Estimate Revision • Dec 01Consensus estimates of losses per share improve by 10%The consensus outlook for earnings per share (EPS) in 2022 has improved. 2022 revenue forecast increased from €66.5m to €67.7m. EPS estimate increased from -€0.59 per share to -€0.53 per share. Healthcare industry in Germany expected to see average net income decline 6.2% next year. Consensus price target of €10.50 unchanged from last update. Share price fell 7.6% to €8.32 over the past week.
Reported Earnings • Nov 24Third quarter 2022 earnings released: €0.02 loss per share (vs €0.11 profit in 3Q 2021)Third quarter 2022 results: €0.02 loss per share (down from €0.11 profit in 3Q 2021). Revenue: €18.7m (up 230% from 3Q 2021). Net loss: €209.0k (down 147% from profit in 3Q 2021). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 98 percentage points per year, which is a significant difference in performance.
Price Target Changed • Nov 16Price target decreased to €10.50Down from €12.50, the current price target is an average from 2 analysts. New target price is 17% above last closing price of €9.00. Stock is down 46% over the past year. The company is forecast to post a net loss per share of €0.59 next year compared to a net loss per share of €0.63 last year.
Reported Earnings • Sep 01Second quarter 2022 earnings released: EPS: €0.30 (vs €0.002 loss in 2Q 2021)Second quarter 2022 results: EPS: €0.30. Revenue: €16.6m (up 206% from 2Q 2021). Net loss: €4.61m (loss widened €4.60m from 2Q 2021). Over the next year, revenue is forecast to grow 48%, compared to a 3.7% growth forecast for the Healthcare industry in Germany.
공시 • Aug 31VITA 34 AG Revises Earnings Guidance for the Financial Year 2022VITA 34 AG revised earnings guidance for the financial year 2022. For the year, the company adjusting the forecast ranges for consolidated sales to EUR 65 to EUR 72 million (previously: EUR 68 to EUR 75 million).
공시 • Aug 24VITA 34 AG to Report Q2, 2022 Results on Aug 30, 2022VITA 34 AG announced that they will report Q2, 2022 results on Aug 30, 2022
공시 • Jun 30+ 1 more updateVITA 34 AG, Annual General Meeting, Jun 29, 2022VITA 34 AG, Annual General Meeting, Jun 29, 2022. Agenda: To consider new Chief Financial Officer; and to consider other matters.
Major Estimate Revision • Jun 07Consensus EPS estimates fall by 85%The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from €73.4m to €68.9m. Losses expected to increase from €0.27 per share to €0.50. Healthcare industry in Germany expected to see average net income growth of 6.5% next year. Consensus price target down from €14.00 to €13.00. Share price rose 2.3% to €11.35 over the past week.
Reported Earnings • Jun 02First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behindFirst quarter 2022 results: €0.18 loss per share (down from €0.01 loss in 1Q 2021). Revenue: €15.5m (up 188% from 1Q 2021). Net loss: €2.81m (loss widened €2.77m from 1Q 2021). Revenue exceeded analyst estimates by 29%. Earnings per share (EPS) missed analyst estimates. Over the next year, revenue is forecast to grow 103%, compared to a 4.8% growth forecast for the industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 72 percentage points per year, which is a significant difference in performance.
공시 • May 25VITA 34 AG to Report Q1, 2022 Results on May 31, 2022VITA 34 AG announced that they will report Q1, 2022 results on May 31, 2022
Reported Earnings • May 02Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2021 results: €0.63 loss per share (down from €0.37 profit in FY 2020). Revenue: €28.4m (up 42% from FY 2020). Net loss: €3.67m (down 343% from profit in FY 2020). Revenue exceeded analyst estimates by 29%. Earnings per share (EPS) missed analyst estimates. Over the next year, revenue is expected to shrink by 17% compared to a 5.9% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.
공시 • May 02Vita 34 Ag Provides Revenue Guidance for the Financial Year 2022VITA 34 AG provided revenue guidance for the financial year 2022. For the year, the company expects consolidated revenues of between EUR 68 million and EUR 75 million for the full year 2022 (2021: EUR 28.4 million).
Price Target Changed • Apr 27Price target increased to €25.00Up from €19.10, the current price target is provided by 1 analyst. New target price is 109% above last closing price of €11.95. Stock is down 29% over the past year. The company is forecast to post earnings per share of €0.46 for next year compared to €0.37 last year.
분석 기사 • Apr 08Is It Too Late To Consider Buying VITA 34 AG (ETR:V3V)?VITA 34 AG ( ETR:V3V ), might not be a large cap stock, but it saw a double-digit share price rise of over 10% in the...
Price Target Changed • Dec 18Price target increased to €21.10Up from €19.10, the current price target is an average from 2 analysts. New target price is 35% above last closing price of €15.60. Stock is up 27% over the past year. The company is forecast to post earnings per share of €0.46 for next year compared to €0.37 last year.
분석 기사 • Dec 07VITA 34 AG's (ETR:V3V) CEO Compensation Looks Acceptable To Us And Here's WhyDespite strong share price growth of 39% for VITA 34 AG ( ETR:V3V ) over the last few years, earnings growth has been...
Reported Earnings • Nov 12Third quarter 2021 earnings released: EPS €0.14 (vs €0.18 in 3Q 2020)The company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: €5.82m (up 7.4% from 3Q 2020). Net income: €575.0k (down 23% from 3Q 2020). Profit margin: 9.9% (down from 14% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.
Reported Earnings • Sep 01Second quarter 2021 earnings releasedThe company reported a soft second quarter result with weaker earnings and weaker control over costs, although revenues improved. Second quarter 2021 results: Revenue: €5.44m (up 11% from 2Q 2020). Net loss: €12.0k (down 102% from profit in 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 2% per year whereas the company’s share price has increased by 3% per year.
Major Estimate Revision • Jun 08Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast fell from €22.0m to €21.8m. EPS estimate rose from €0.47 to €0.52. Net income forecast to grow 92% next year vs 92% growth forecast for Healthcare industry in Germany. Consensus price target of €19.10 unchanged from last update. Share price was steady at €17.05 over the past week.
공시 • Jun 02VITA 34 AG (XTRA:V3V) entered into a Business Combination Agreement to acquire Polski Bank Komórek Macierzystych S.A. (WSE:BKM) (PKBM) from AOC Health GmbH, Jakub Baran, Tomasz Baran and others for approximately PLN 840 million.VITA 34 AG (XTRA:V3V) entered into a Business Combination Agreement to acquire Polski Bank Komórek Macierzystych S.A. (WSE:BKM) (PKBM) from AOC Health GmbH, Jakub Baran, Tomasz Baran and others for approximately PLN 840 million on May 31, 2021. Transaction to be carried out by way of a contribution in kind at an exchange of 1.3 new Vita 34 shares in exchange for one (1) share of PBKM. Under the transaction, AOC Health GmbH will sell 5.743221 million shares representing 62.4% stake, Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A. will sell 1.282201 million shares representing 13.93% stake and Jakub Baran will sell 0.395875 million shares representing 4.3% stake. Major PBKM shareholders have already agreed to contribute to Vita 34 a total of 6.363170 million PBKM shares (representing approximately 69.13% of the current share capital of PBKM). The combined Group will be listed on the Frankfurt Stock Exchange, with Vita 34 as the listed parent company. These shareholders include (inter alia) AOC Health GmbH, Jakub Baran, President and Chief Executive officer of the PBKM Management Board, and Tomasz Baran, Vice President and Deputy Chief Executive officer of the PBKM Management Board. The new Vita 34 shares to be issued under the Proposed Transaction shall be created by way of a capital increase in kind still to be resolved upon by Vita 34’s shareholders. For purposes of resolving the capital increase, Vita 34 will convene an extraordinary general meeting for July 13, 2021, with the ordinary annual general meeting originally scheduled for June 30, 2021 to be postponed and likely to take place in the fourth quarter of 2021. At the extraordinary general meeting, Vita 34’s share capital shall be increased by up to €12.280560 million against contribution in kind by issuing up to 12,280,560 no-par value registered shares. Completion of the Exchange Offer is subject to a number of conditions, including the achievement of a minimum acceptance level of 95% of PBKM’s outstanding shares and the absence of any material adverse change and no material adverse infringements occurring at PBKM. Transaction has been approved by the Supervisory Board of Vita 34 AG. The Management Board PBKM intends to support the Proposed Transaction and recommend to the PBKM shareholders to accept the Exchange Offer. Transaction is expected to complete by the end of October 2021. VITA 34 AG appointed ValueTrust Financial Advisors SE as an independent expert under the transaction.
Reported Earnings • Jun 01First quarter 2021 earnings releasedThe company reported a soft first quarter result with weaker earnings and weaker control over costs, although revenues improved. First quarter 2021 results: Revenue: €5.38m (up 15% from 1Q 2020). Net loss: €38.0k (down 110% from profit in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.
공시 • Jun 01VITA 34 AG Provides Earnings Guidance for the Year 2021VITA 34 AG maintained guidance for 2021. The Management Board maintains its guidance for the full fiscal year 2021 of Vita 34 AG (prior to the planned merger) published in the context of the Annual Report 2020.
분석 기사 • May 12Is It Too Late To Consider Buying VITA 34 AG (ETR:V3V)?While VITA 34 AG ( ETR:V3V ) might not be the most widely known stock at the moment, it saw a significant share price...
Major Estimate Revision • Apr 07Consensus EPS estimates fall to €0.47The consensus outlook for earnings per share (EPS) in 2021 has deteriorated. 2021 revenue forecast decreased from €22.3m to €22.0m. EPS estimate also fell from €0.61 to €0.47. Net income forecast to grow 26% next year vs 16% growth forecast for Healthcare industry in Germany. Consensus price target up from €20.00 to €21.00. Share price rose 2.3% to €15.25 over the past week.
분석 기사 • Apr 03Earnings Miss: VITA 34 AG Missed EPS By 29% And Analysts Are Revising Their ForecastsVITA 34 AG ( ETR:V3V ) missed earnings with its latest full-year results, disappointing overly-optimistic forecasters...
Reported Earnings • Apr 01Full year 2020 earnings released: EPS €0.37 (vs €0.18 in FY 2019)The company reported a solid full year result with improved earnings and profit margins, although revenues were flat. Full year 2020 results: Revenue: €20.1m (flat on FY 2019). Net income: €1.51m (up 104% from FY 2019). Profit margin: 7.5% (up from 3.7% in FY 2019). Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.
분석 기사 • Mar 25VITA 34 AG's (ETR:V3V) Intrinsic Value Is Potentially 56% Above Its Share PriceHow far off is VITA 34 AG ( ETR:V3V ) from its intrinsic value? Using the most recent financial data, we'll take a look...
공시 • Mar 17+ 3 more updatesVITA 34 AG to Report Q1, 2021 Results on May 11, 2021VITA 34 AG announced that they will report Q1, 2021 results on May 11, 2021
분석 기사 • Mar 10Should You Be Adding VITA 34 (ETR:V3V) To Your Watchlist Today?Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...
분석 기사 • Feb 22Here's Why VITA 34 (ETR:V3V) Can Manage Its Debt ResponsiblyDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Is New 90 Day High Low • Feb 10New 90-day high: €13.95The company is up 11% from its price of €12.60 on 11 November 2020. The German market is also up 11% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it outperformed the Healthcare industry, which is down 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €22.83 per share.
분석 기사 • Feb 05Is It Too Late To Consider Buying VITA 34 AG (ETR:V3V)?VITA 34 AG ( ETR:V3V ), might not be a large cap stock, but it led the XTRA gainers with a relatively large price hike...
Is New 90 Day High Low • Jan 23New 90-day high: €13.05The company is up 4.0% from its price of €12.55 on 23 October 2020. The German market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €22.88 per share.
분석 기사 • Jan 18Can Mixed Financials Have A Negative Impact on VITA 34 AG's 's (ETR:V3V) Current Price Momentum?Most readers would already know that VITA 34's (ETR:V3V) stock increased by 4.5% over the past month. However, we...
분석 기사 • Jan 02Did You Participate In Any Of VITA 34's (ETR:V3V) Fantastic 201% Return ?The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...
공시 • Dec 19VITA 34 AG, Annual General Meeting, Jun 30, 2021VITA 34 AG, Annual General Meeting, Jun 30, 2021.
분석 기사 • Dec 18How Is VITA 34's (ETR:V3V) CEO Compensated?This article will reflect on the compensation paid to Wolfgang Knirsch who has served as CEO of VITA 34 AG ( ETR:V3V...
분석 기사 • Dec 01Should You Be Adding VITA 34 (ETR:V3V) To Your Watchlist Today?Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...
Price Target Changed • Nov 26Price target raised to €17.50Up from €15.00, the current price target is an average from 2 analysts. The new target price is 39% above the current share price of €12.55. As of last close, the stock is down 4.9% over the past year.